Rise of illicit medetomidine use: A worrisome trend.

Background and objectives: Medetomidine is a sedative approved by the FDA for veterinary use, but it is not authorized for human use. Its increasing presence alongside illegal opioids like fentanyl contributes to a rise in fatal overdoses across the U.S. While it is more potent than xylazine, knowledge surrounding medetomidine's role as an adulterant remains limited. This review investigates existing human data regarding its illicit use and overdose symptoms and highlights the evolving issue.

Methods: This review compiles case reports, law enforcement findings, and human studies to assess the role of medetomidine in opioid overdoses. We emphasize overdose symptoms, treatment challenges, and clinical outcomes, drawing from cases in U.S. cities experiencing rising overdose rates associated with this sedative.

Results: The review reveals a troubling trend of increasing fatalities related to medetomidine adulteration, particularly in urban areas. Medetomidine's sedative effects complicate the management of opioid overdoses, often leaving many cases unrecognized due to the overlap of symptoms. The rising incidents of seizures and deaths underscore the urgent need for public health action.

Discussion and conclusions: The growing use of medetomidine as an opioid adulterant calls for further research, increased awareness among healthcare professionals and emergency responders, and enhanced diagnostic screening methods. Specific treatment protocols for medetomidine overdoses are crucial, and laboratory testing should be expanded to identify this substance.

Scientific significance: This review highlights the growing prevalence of medetomidine, which has surpassed xylazine also in some areas, and advocates for strengthened public health efforts to address this emerging crisis.